MA46219A - Composés de co-agonistes du glucagon et du glp-1 - Google Patents
Composés de co-agonistes du glucagon et du glp-1Info
- Publication number
- MA46219A MA46219A MA046219A MA46219A MA46219A MA 46219 A MA46219 A MA 46219A MA 046219 A MA046219 A MA 046219A MA 46219 A MA46219 A MA 46219A MA 46219 A MA46219 A MA 46219A
- Authority
- MA
- Morocco
- Prior art keywords
- glp
- glucagon
- agonist compounds
- alcoholic
- nafld
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title abstract 2
- 108060003199 Glucagon Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 229960004666 glucagon Drugs 0.000 title abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102100040918 Pro-glucagon Human genes 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La présente invention concerne des composés de co-agonistes du glucagon et du glp-1 qui sont utiles dans le traitement du diabète de type 2, de l'obésité, de la stéatose hépatique non alcoolique (nafld) et/ou de la stéatohépatite non alcoolique (nash) p-20637
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562182847P | 2015-06-22 | 2015-06-22 | |
PCT/US2016/037818 WO2016209707A1 (fr) | 2015-06-22 | 2016-06-16 | Composés de co-agonistes du glucagon et du glp-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA46219A true MA46219A (fr) | 2018-04-25 |
MA46219B1 MA46219B1 (fr) | 2020-12-31 |
Family
ID=56289604
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054407A MA54407A (fr) | 2015-06-22 | 2016-06-16 | Composés de co-agonistes du glucagon et du glp-1 |
MA46219A MA46219B1 (fr) | 2015-06-22 | 2016-06-16 | Composés de co-agonistes du glucagon et du glp-1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054407A MA54407A (fr) | 2015-06-22 | 2016-06-16 | Composés de co-agonistes du glucagon et du glp-1 |
Country Status (40)
Country | Link |
---|---|
US (1) | US9938335B2 (fr) |
EP (2) | EP3310371B1 (fr) |
JP (4) | JP6585197B2 (fr) |
KR (2) | KR102034607B1 (fr) |
CN (2) | CN107735100B (fr) |
AR (1) | AR104932A1 (fr) |
AU (1) | AU2016283984B2 (fr) |
BR (1) | BR112017024684A2 (fr) |
CA (1) | CA2987489A1 (fr) |
CL (1) | CL2017003185A1 (fr) |
CO (1) | CO2018000078A2 (fr) |
CR (1) | CR20170534A (fr) |
CY (1) | CY1123591T1 (fr) |
DK (1) | DK3310371T3 (fr) |
DO (1) | DOP2017000303A (fr) |
EA (1) | EA038720B1 (fr) |
EC (1) | ECSP17084280A (fr) |
ES (1) | ES2833458T3 (fr) |
HK (1) | HK1245669A1 (fr) |
HR (1) | HRP20201881T1 (fr) |
HU (1) | HUE052684T2 (fr) |
IL (4) | IL307657A (fr) |
JO (1) | JO3686B1 (fr) |
LT (1) | LT3310371T (fr) |
MA (2) | MA54407A (fr) |
MD (1) | MD3310371T2 (fr) |
MX (1) | MX2017016198A (fr) |
MY (1) | MY190210A (fr) |
NZ (1) | NZ737050A (fr) |
PE (2) | PE20180523A1 (fr) |
PH (1) | PH12017502359B1 (fr) |
PL (1) | PL3310371T3 (fr) |
PT (1) | PT3310371T (fr) |
RS (1) | RS61107B1 (fr) |
SI (1) | SI3310371T1 (fr) |
SV (1) | SV2017005594A (fr) |
TN (1) | TN2017000531A1 (fr) |
TW (3) | TWI669309B (fr) |
UA (1) | UA122692C2 (fr) |
WO (1) | WO2016209707A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR104932A1 (es) * | 2015-06-22 | 2017-08-23 | Lilly Co Eli | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
CN108299553B (zh) * | 2017-01-13 | 2021-07-16 | 博瑞生物医药(苏州)股份有限公司 | 胃泌酸调节素修饰物 |
CN111194223B (zh) * | 2017-09-19 | 2023-10-24 | 免疫功坊股份有限公司 | 与白蛋白具有较佳结合亲和力的药物分子 |
CN114920818B (zh) * | 2017-11-06 | 2024-02-27 | 深圳市图微安创科技开发有限公司 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 |
TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
WO2019140025A1 (fr) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
KR20210091230A (ko) * | 2018-11-12 | 2021-07-21 | 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. | 글루카곤 유도 펩티드 및 이의 용도 |
CN111171135B (zh) * | 2018-11-12 | 2023-04-07 | 天津药物研究院有限公司 | 具有双重受体激动作用的胰高血糖素衍生肽及其用途 |
CN111423506B (zh) * | 2019-11-08 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种glp-1化合物 |
TWI770781B (zh) * | 2020-01-23 | 2022-07-11 | 美商美國禮來大藥廠 | Gip/glp1共促效劑化合物 |
CN113336840B (zh) * | 2020-03-02 | 2022-09-23 | 武汉帕肽生物医药有限责任公司 | 订书肽、其制备方法和用途 |
EP4119570A4 (fr) * | 2020-03-11 | 2023-10-11 | Anygen Co., Ltd. | Composition anti-diabète et anti-obésité comprenant un nouveau composé |
CN111410686B (zh) * | 2020-03-18 | 2021-02-26 | 南京枫璟生物医药科技有限公司 | Glp-1r激活剂的分子改构及其二聚体在治疗代谢病中的应用 |
EP4132960A2 (fr) * | 2020-04-10 | 2023-02-15 | Fresenius Kabi Oncology Limited | Procédé amélioré pour la préparation d'une chaîne latérale de sémaglutide |
CN115515641A (zh) | 2020-04-29 | 2022-12-23 | 株式会社原真生物技术 | 新型蛋白质结合物及其非酒精性脂肪性肝炎、肥胖及糖尿病的预防或治疗用途 |
AR122579A1 (es) * | 2020-06-12 | 2022-09-21 | Lilly Co Eli | Proceso para preparar un agonista dual glp-1 / glucagón |
MX2023000698A (es) * | 2020-07-15 | 2023-04-18 | Hanmi Pharmaceutical Co Ltd | Uso terapeutico del derivado de glucagon o conjugado del mismo para enfermedades hepaticas. |
CN116635008A (zh) | 2020-12-22 | 2023-08-22 | 伊莱利利公司 | 治疗肽制剂 |
CN112898405B (zh) * | 2021-01-22 | 2023-02-28 | 深圳市图微安创科技开发有限公司 | 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用 |
CN113429471B (zh) * | 2021-07-19 | 2022-12-23 | 青岛博睿精创科技有限公司 | 长效glp-1多肽类似物及其制备方法和应用 |
WO2023016346A1 (fr) * | 2021-08-10 | 2023-02-16 | 南京明德新药研发有限公司 | Composé polypeptidique contenant un pont lactame |
KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
WO2023088143A1 (fr) * | 2021-11-19 | 2023-05-25 | 南京明德新药研发有限公司 | Polypeptides contenant des agrafes et leur application |
TW202404996A (zh) | 2022-04-04 | 2024-02-01 | 美商美國禮來大藥廠 | 製備glp-1/升糖素雙重促效劑之方法 |
CN116970064A (zh) * | 2022-04-29 | 2023-10-31 | 苏州星洲生物科技有限公司 | Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途 |
WO2023231730A2 (fr) * | 2022-06-01 | 2023-12-07 | 信达生物制药(苏州)有限公司 | Méthode de traitement utilisant du mazdutide |
WO2023235724A1 (fr) | 2022-06-01 | 2023-12-07 | Eli Lilly And Company | Procédés d'utilisation d'un co-agoniste gcg/glp1 pour une thérapie |
CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
WO2024050289A1 (fr) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions pour administration orale |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2778047A1 (fr) * | 1998-12-07 | 2000-06-15 | Ipsen Pharma S.A.S | Analogues du glp-1 |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
CA2852177A1 (fr) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Co-agonistes du recepteur glucagon/glp-1 |
WO2011075393A2 (fr) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Co-agonistes du récepteur du glucagon/glp-i |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
RU2012136450A (ru) * | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
CN103748109A (zh) | 2011-06-22 | 2014-04-23 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共同激动剂 |
WO2013004983A1 (fr) * | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Nouveaux composés et leurs effets sur le comportement alimentaire |
WO2013074910A1 (fr) * | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Peptides de la superfamille du glucagon présentant une action sur les récepteurs aux glucocorticoïdes |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
WO2014041375A1 (fr) * | 2012-09-17 | 2014-03-20 | Imperial Innovations Limited | Analogues peptidiques du glucagon et du glp1 |
UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
US20160058881A1 (en) * | 2013-03-15 | 2016-03-03 | Indiana University Research And Technology Corporation | Prodrugs with prolonged action |
AR104932A1 (es) * | 2015-06-22 | 2017-08-23 | Lilly Co Eli | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
-
2016
- 2016-06-08 AR ARP160101696A patent/AR104932A1/es unknown
- 2016-06-08 TW TW105118223A patent/TWI669309B/zh active
- 2016-06-08 TW TW107124831A patent/TWI700291B/zh active
- 2016-06-08 TW TW109123454A patent/TWI783244B/zh active
- 2016-06-09 JO JOP/2016/0116A patent/JO3686B1/ar active
- 2016-06-16 IL IL307657A patent/IL307657A/en unknown
- 2016-06-16 KR KR1020177036488A patent/KR102034607B1/ko active IP Right Grant
- 2016-06-16 AU AU2016283984A patent/AU2016283984B2/en active Active
- 2016-06-16 MA MA054407A patent/MA54407A/fr unknown
- 2016-06-16 WO PCT/US2016/037818 patent/WO2016209707A1/fr active Application Filing
- 2016-06-16 EA EA201792562A patent/EA038720B1/ru unknown
- 2016-06-16 JP JP2017566081A patent/JP6585197B2/ja active Active
- 2016-06-16 RS RS20201437A patent/RS61107B1/sr unknown
- 2016-06-16 US US15/184,116 patent/US9938335B2/en active Active
- 2016-06-16 SI SI201630939T patent/SI3310371T1/sl unknown
- 2016-06-16 PT PT167332683T patent/PT3310371T/pt unknown
- 2016-06-16 CN CN201680036771.3A patent/CN107735100B/zh active Active
- 2016-06-16 IL IL285231A patent/IL285231B/en unknown
- 2016-06-16 TN TNP/2017/000531A patent/TN2017000531A1/en unknown
- 2016-06-16 LT LTEP16733268.3T patent/LT3310371T/lt unknown
- 2016-06-16 MD MDE20180406T patent/MD3310371T2/ro unknown
- 2016-06-16 ES ES16733268T patent/ES2833458T3/es active Active
- 2016-06-16 CR CR20170534A patent/CR20170534A/es unknown
- 2016-06-16 DK DK16733268.3T patent/DK3310371T3/da active
- 2016-06-16 PL PL16733268T patent/PL3310371T3/pl unknown
- 2016-06-16 EP EP16733268.3A patent/EP3310371B1/fr active Active
- 2016-06-16 MA MA46219A patent/MA46219B1/fr unknown
- 2016-06-16 CA CA2987489A patent/CA2987489A1/fr active Pending
- 2016-06-16 PE PE2017002765A patent/PE20180523A1/es unknown
- 2016-06-16 KR KR1020197030220A patent/KR102544419B1/ko active IP Right Grant
- 2016-06-16 CN CN202111209577.XA patent/CN113956348A/zh active Pending
- 2016-06-16 BR BR112017024684A patent/BR112017024684A2/pt active Search and Examination
- 2016-06-16 MX MX2017016198A patent/MX2017016198A/es unknown
- 2016-06-16 EP EP20198508.2A patent/EP3785724A1/fr active Pending
- 2016-06-16 IL IL294099A patent/IL294099B2/en unknown
- 2016-06-16 MY MYPI2017704914A patent/MY190210A/en unknown
- 2016-06-16 PE PE2022000797A patent/PE20231639A1/es unknown
- 2016-06-16 NZ NZ737050A patent/NZ737050A/en unknown
- 2016-06-16 UA UAA201712096A patent/UA122692C2/uk unknown
- 2016-06-16 HU HUE16733268A patent/HUE052684T2/hu unknown
-
2017
- 2017-11-16 IL IL255723A patent/IL255723B/en unknown
- 2017-12-13 CL CL2017003185A patent/CL2017003185A1/es unknown
- 2017-12-15 SV SV2017005594A patent/SV2017005594A/es unknown
- 2017-12-19 DO DO2017000303A patent/DOP2017000303A/es unknown
- 2017-12-19 PH PH12017502359A patent/PH12017502359B1/en unknown
- 2017-12-21 EC ECIEPI201784280A patent/ECSP17084280A/es unknown
-
2018
- 2018-01-05 CO CONC2018/0000078A patent/CO2018000078A2/es unknown
- 2018-04-26 HK HK18105443.2A patent/HK1245669A1/zh unknown
-
2019
- 2019-09-04 JP JP2019161068A patent/JP6985345B2/ja active Active
-
2020
- 2020-11-16 CY CY20201101082T patent/CY1123591T1/el unknown
- 2020-11-26 HR HRP20201881TT patent/HRP20201881T1/hr unknown
-
2021
- 2021-11-25 JP JP2021190654A patent/JP7386218B2/ja active Active
-
2023
- 2023-11-13 JP JP2023193059A patent/JP2024016243A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46219A (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
MA41013B1 (fr) | Compositions comprenant des souches bactériennes | |
MA44322A (fr) | Compositions comprenant des souches bactériennes | |
MA42471A (fr) | Compositions comprenant des souches bactériennes | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
MA44890A (fr) | Compositions comprenant des souches bactériennes | |
DOP2009000269A (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
TN2017000352A1 (en) | Antibodies to tau and uses thereof | |
MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
MA53875A (fr) | Traitement avec des compositions d'igg hautement sialylées | |
MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
WO2018071504A3 (fr) | Méthodes de traitement de maladies | |
EA201691572A1 (ru) | Ингибитор белка-переносчика эфира холестерина (cetp) и фармацевтические композиции, содержащие указанный ингибитор для применения для лечения или предотвращения сердечно-сосудистых заболеваний | |
MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
MX2017006747A (es) | Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis. | |
IN2015MU02440A (fr) | ||
MA54067A (fr) | Traitement et prévention de l'éjaculation précoce (pe) | |
MA45200A (fr) | Compositions comprenant des souches bactériennes |